VEGFR-2 antagonist SU5416 attenuates bleomycin-induced pulmonary fibrosis in mice
Xuemei Ou(City University of Hong Kong), Lei Chen(Sichuan University), Wancheng Li(Zhongyuan University of Technology), Xun Wang(Peking University), Ke Wang(Zhejiang Chinese Medical University), Yanping Li(Sichuan University), Tao Wang(Heilongjiang University of Chinese Medicine), Fuqiang Wen(Sichuan University), Yulin Feng(Sichuan University), Shangfu Zhang(Sichuan University), Xiangyang Huang(Sichuan University), Daishun Liu(Zunyi Medical University)
Cited by 60
Related Papers
RETRACTED: 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study
|The Lancet|2021|4.3k
Prevalence and risk factors of chronic obstructive pulmonary disease in China (the China Pulmonary Health [CPH] study): a national cross-sectional study
|The Lancet|2018|1.8k
6-month consequences of COVID-19 in patients discharged from hospital: a cohort study
|The Lancet|2023|892
Prevalence, risk factors, and management of asthma in China: a national cross-sectional study
|The Lancet|2019|773
The Multifaceted Therapeutic Role of N-Acetylcysteine (NAC) in Disorders Characterized by Oxidative Stress
|Current Neuropharmacology|2020|283